Epilepsy, a complex spectrum of seizure disorders, which affects about 3.4 million people nationwide, making it the fourth most common neurological disease in the United States. While anti seizure medicines (ASMs) are the first line of treatment, 50% of people living with epilepsy (PWE) experience adverse drug effects that lessen medication adherence and quality of life (QoL). For nearly five years, a team of interdisciplinary researchers at the University of Washington, which included H. Steve White (Pharmacy), Andy Stergachis (Pharmacy…
Initiative-funded pilot develops training for pharmacists to treat people with epilepsy









